Warsaw, Poland – Scientists at the Institute of Physical Chemistry of the Polish Academy of Sciences (IPC PAS) and the University of Warsaw (UW) have developed a new method for growing lab-grown blood vessels with precise control over their structure using magnetic fields. The breakthrough, announced March 20, 2026, offers a potential path to reduce reliance on animal testing in drug development and personalized medicine.
The research team, led by Dr. Hab. J. Guzowski and Prof. P. Szymczak, engineered a system where endothelial cells are coated onto the surface of superparamagnetic microparticles. These particles can then be arranged into specific patterns using external magnetic fields generated by an array of micromagnets, effectively dictating the architecture of the growing vascular network. This approach addresses a key challenge in creating reliable, human-relevant tissue models – achieving precise control over microvascular growth.
Traditional drug development relies heavily on animal studies to predict how drugs will affect the human body. However, significant differences between species often lead to inaccurate predictions, increasing the cost and duration of the development process, and raising ethical concerns. Researchers have been working to create in vitro tissue constructs using human cells that more accurately mimic the complexities of human vascular systems, but controlling the growth of these microvascular networks has proven hard.
“The patterning is achieved via directed-assembly using external magnetic fields,” explained Dr. Katarzyna Rojek, the first author of the research work, confirming the 3D structural integrity of the microvessels and the presence of characteristic marker proteins of healthy blood vessels. The team’s work, detailed in recent publications, demonstrates the potential to create vascular microenvironments with well-defined micro-architecture.
The implications of this technology extend beyond drug testing. The ability to create precisely patterned vascular networks could also be used to study the fundamental processes of angiogenesis – the formation of new blood vessels – and vascular disease. The research team has not yet announced plans for clinical trials or commercialization, but the technology is expected to accelerate the development of personalized medicine approaches.
The development of this system comes as the medical community increasingly focuses on coronary microvascular dysfunction, a condition affecting up to 50% of patients with chest pain who do not display blockages in major arteries. The Microvascular Network (MVN), a community of clinicians dedicated to the diagnosis and management of coronary microvascular dysfunction, recently highlighted research demonstrating the potential of the coronary sinus reducer to improve angina and quality of life in patients with this condition. While not directly related to the Polish research, this underscores the growing emphasis on understanding and treating microvascular issues.
Leave a Reply